Nurix Therapeutics
NRIX
117 hedge funds and large institutions have $566M invested in Nurix Therapeutics in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 50 increasing their positions, 32 reducing their positions, and 25 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 32
0.59% less ownership
Funds ownership: 90.62% → 90.03% (-0.59%)
6% less funds holding
Funds holding: 125 → 117 (-8)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
32% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 25
52% less capital invested
Capital invested by funds: $1.17B → $566M (-$604M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$13.2M |
| 2 |
Morgan Stanley
New York
|
+$10.6M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$6.18M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$6.09M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$5.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$15.4M |
| 2 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$13.7M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$9.29M |
| 4 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$8.88M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$6.63M |
NRIX Hedge Fund Activity: Q1 2022 in Review
117 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q1 2022, worth a combined $566M — down 52% from $1.17B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of NRIX and 17 opened new positions — a net loss of 8 holders — while 32 trimmed existing stakes and 50 added.
The largest buyer was State Street, adding an estimated $13.2M. The largest seller was Jennison Associates, cutting an estimated $15.4M.
- 117 institutional investors held Nurix Therapeutics (NRIX) as of Q1 2022, down from 125 in Q4 2021.
- Funds reported $566M of Nurix Therapeutics stock for Q1 2022, down 52% quarter-over-quarter.
- 17 funds opened new Nurix Therapeutics positions in Q1 2022 and 25 closed out, a net change of -8 holders.
- The largest Nurix Therapeutics buyer in Q1 2022 was State Street, an estimated $13.2M added.
- The largest Nurix Therapeutics seller in Q1 2022 was Jennison Associates, an estimated $15.4M sold.
Based on aggregated 13F filings for Q1 2022.